Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00410202 · ClinicalTrials.gov registry record · Phase 3

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

A Phase 3 study of Hepatitis B， Chronic, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
629
Enrollment target
20
Study locations

NCT00410202 is a Phase 3 study of Hepatitis B， Chronic that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 629 participants, above the 501-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00410202, a Phase 3 study of Hepatitis B， Chronic, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
629 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

Conditions Studied

Hepatitis B， Chronic

Interventions

  • DRUG Lamivudine
  • DRUG Tenofovir
  • DRUG Entecavir
  • DRUG Adefovir

Study Locations (20)

Other

  • Local Institution - Athens
  • Local Institution - Tai Po
  • Local Institution - Ahmedabad
  • Local Institution - Chandigarh
  • Local Institution - Indore
  • Local Institution - Ludhiana
  • Local Institution - New Delhi
  • Local Institution - Vellore
  • Local Institution - Jakarta
  • Local Institution - Antella, Firenze
  • Local Institution - Kuala Lumpur

New South Wales

  • Local Institution - Concord
  • Local Institution - Randwick

Connecticut

  • University Of Connecticut Health Center - Farmington

Rio Grande do Sul

  • Local Institution - Porto Alegre Rs

Alberta

  • Local Institution - Calgary

Hong Kong

  • Local Institution - Hong Kong

New Territories

  • Local Institution - Shatin

Uttar Pradesh

  • Local Institution - Lucknow

Trial Details

FieldValue
Enrollment Target 629 participants
Start Date 2008-03
Est. Completion 2012-07
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00410202

The ClinicalTrials.gov registry entry for NCT00410202 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 629 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 501-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (26% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis B， Chronic appearing as the primary indexed condition, and to 4 interventions - of which Lamivudine is the first listed.

NCT00410202 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New South Wales, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00410202 about?

NCT00410202 is a clinical study titled "Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus". The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

What is the current status of trial NCT00410202?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2008-03. Estimated completion is 2012-07.

What conditions does trial NCT00410202 study?

This clinical trial studies the following conditions: Hepatitis B， Chronic.

What interventions are being tested in trial NCT00410202?

The interventions under investigation include: Lamivudine (DRUG), Tenofovir (DRUG), Entecavir (DRUG), Adefovir (DRUG).

Who is sponsoring clinical trial NCT00410202?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00410202 being conducted?

This trial has 20 study locations across Connecticut, New South Wales, Rio Grande do Sul, Alberta, Hong Kong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis B， Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis B， Chronic

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.